Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,654 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 1,654 shares of the business's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $44.90, for a total transaction of $74,264.60. Following the transaction, the chief executive officer now owns 673,064 shares in the company, valued at approximately $30,220,573.60. This trade represents a 0.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded up $0.32 during trading on Thursday, hitting $49.22. The company had a trading volume of 486,879 shares, compared to its average volume of 940,682. The company has a fifty day simple moving average of $45.51 and a two-hundred day simple moving average of $46.72. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -13.67 and a beta of 1.82. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Analyst Ratings Changes

Several research analysts recently weighed in on TWST shares. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Robert W. Baird upped their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. Finally, Barclays decreased their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $51.90.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Signaturefd LLC raised its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth $61,000. Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience during the 3rd quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after buying an additional 381 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.